Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Proceeds

Core Viewpoint - Autonomix Medical, Inc. has announced agreements for the immediate exercise of existing warrants, allowing the purchase of up to 1,477,596 shares of common stock at a reduced exercise price of $1.723 per share, expected to generate approximately $2.5 million in gross proceeds [1][4]. Group 1: Warrant Exercise and Financial Details - The company has entered into agreements with certain warrant holders for the immediate exercise of outstanding warrants, which were originally issued in November 2024 [1]. - The gross proceeds from the exercise of these warrants are anticipated to be around $2.5 million before placement agent fees [1]. - New unregistered warrants will be issued for the immediate exercise, allowing the purchase of the same number of shares at the same exercise price of $1.723 per share, valid for five and a half years [3]. Group 2: Transaction Closing and Use of Proceeds - The transaction is expected to close on or about July 23, 2025, pending customary closing conditions [4]. - The net proceeds from this offering will be utilized for working capital and general corporate purposes [4]. Group 3: Company Overview and Technology - Autonomix Medical is focused on advancing innovative technologies for diagnosing and treating diseases of the nervous system, utilizing a catheter-based microchip sensing array [7]. - The company is initially developing its technology for pain treatment, particularly targeting pancreatic cancer, and aims to address various conditions across a wide disease spectrum [8].